Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- TSTA-3 P-35-B 35B anti-biotic CD-4+ MS Escherichia
- Product Overview:
GDP-L-Fucose synthase, encoded by the gene TSTA3, is an NADP(H)-binding protein that catalyzes the final step in the synthesis of GDP-L-fucose from GDP-D-mannose.{42819,42820} It converts GDP-4-keto-6-deoxy-D-mannose to GDP-L-fucose via a two-step reaction consisting of epimerization followed by NADPH-dependent reduction. GDP-L-Fucose synthase exists as a homodimer and is comprised of an N-terminal NADPH-binding domain and a C-terminal substrate-binding domain. TSTA3-/- mice exhibit increases in colonic inflammation, dysplasia, and epithelial permeability, which are reversed following addition of fucose to the diet.{42821} These mice also exhibit alterations in gut microflora and increased bacterial burden in colon transluminal tissue and feces when fed a normal diet versus a fucose-supplemented diet, and the colonic effects of TSTA3 deletion can be reversed following administration of antibiotics. GDP-L-Fucose synthase has been identified as an autoantigen that can be recognized by CD4+ T cells derived from patients with multiple sclerosis.{42822} Expression of GDP-L-fucose synthase in primary tumor tissue samples from patients with esophageal squamous cell carcinoma (ESCC) positively correlates with increased clinical stage, lymph node metastasis, and poor prognosis.{42823}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.